Literature DB >> 30228771

Exposure to Ticks and their Pathogens in Northeast Missouri.

Deborah A Hudman1.   

Abstract

While the prevalence of human pathogens has been quantified in ticks in Adair County, Missouri, the prevalence of residents acquiring tick-borne diseases and seeking medical treatment has not. A public survey (n=109) revealed that 96% of respondents reported finding attached ticks on their person; of these, 38% developed symptoms post tick bite; of these, 55% reported consultation with a health care provider. Overall, 89% of practitioners surveyed had treated at least one patient for tick-borne disease. Rocky Mountain spotted fever and Lyme disease were the most common illnesses diagnosed, however, the only confirmed cases reported by Missouri Department of Health and Senior Services from 2013-2017 were ehrlichiosis. Results from these surveys indicate that exposure to ticks is common and ehrlichiosis infections are likely underdiagnosed while Rocky Mountain spotted fever and Lyme disease are likely overdiagnosed.

Entities:  

Mesh:

Year:  2018        PMID: 30228771      PMCID: PMC6140261     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  17 in total

1.  First isolation and cultivation of Borrelia burgdorferi sensu lato from Missouri.

Authors:  J H Oliver; T M Kollars; F W Chandler; A M James; E J Masters; R S Lane; L O Huey
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

2.  Tick-borne rickettsioses in America: unanswered questions and emerging diseases.

Authors:  Philippe Parola; Marcelo B Labruna; Didier Raoult
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

3.  Ehrlichia and spotted fever group Rickettsiae surveillance in Amblyomma americanum in Virginia through use of a novel six-plex real-time PCR assay.

Authors:  David N Gaines; Darwin J Operario; Suzanne Stroup; Ellen Stromdahl; Chelsea Wright; Holly Gaff; James Broyhill; Joshua Smith; Douglas E Norris; Tyler Henning; Agape Lucas; Eric Houpt
Journal:  Vector Borne Zoonotic Dis       Date:  2014-04-18       Impact factor: 2.133

4.  Tick-borne diseases in North Carolina: is "Rickettsia amblyommii" a possible cause of rickettsiosis reported as Rocky Mountain spotted fever?

Authors:  Charles S Apperson; Barry Engber; William L Nicholson; Daniel G Mead; Jeffrey Engel; Michael J Yabsley; Kathy Dail; Joey Johnson; D Wesley Watson
Journal:  Vector Borne Zoonotic Dis       Date:  2008-10       Impact factor: 2.133

5.  Human Infections by Multiple Spotted Fever Group Rickettsiae in Tennessee.

Authors:  Josie Delisle; Nicole L Mendell; Annica Stull-Lane; Karen C Bloch; Donald H Bouyer; Abelardo C Moncayo
Journal:  Am J Trop Med Hyg       Date:  2016-03-28       Impact factor: 2.345

6.  Testing practices and volume of non-Lyme tickborne diseases in the United States.

Authors:  Neeta P Connally; Alison F Hinckley; Katherine A Feldman; Melissa Kemperman; David Neitzel; Siok-Bi Wee; Jennifer L White; Paul S Mead; James I Meek
Journal:  Ticks Tick Borne Dis       Date:  2015-10-30       Impact factor: 3.744

7.  Detection of Rickettsia amblyommii in association with a tick bite rash.

Authors:  Sarah A Billeter; Hunter L Blanton; Susan E Little; Michael G Levy; Edward B Breitschwerdt
Journal:  Vector Borne Zoonotic Dis       Date:  2007       Impact factor: 2.133

Review 8.  Tick-induced allergies: mammalian meat allergy, tick anaphylaxis and their significance.

Authors:  Sheryl van Nunen
Journal:  Asia Pac Allergy       Date:  2015-01-28

9.  Social-ecological factors determine spatial variation in human incidence of tick-borne ehrlichiosis.

Authors:  B R Bayles; B F Allan
Journal:  Epidemiol Infect       Date:  2013-11-26       Impact factor: 4.434

10.  First detection of heartland virus (Bunyaviridae: Phlebovirus) from field collected arthropods.

Authors:  Harry M Savage; Marvin S Godsey; Amy Lambert; Nicholas A Panella; Kristen L Burkhalter; Jessica R Harmon; R Ryan Lash; David C Ashley; William L Nicholson
Journal:  Am J Trop Med Hyg       Date:  2013-07-22       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.